{"transactions":[{"id":706835,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":true,"shares":17786,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option shall vest in full on the earlier of:  (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the East Pillar 2026 Irrevocable Trust (the \"Trust\"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity.  The reporting person and certain of his immediate family members are beneficiaries of the Trust."}],"balance_after":17786,"derivative":{"exercise_price":29.46,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":17786},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706834,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":false,"shares":17786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option shall vest in full on the earlier of:  (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date."}],"balance_after":0,"derivative":{"exercise_price":29.46,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":17786},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706833,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":true,"shares":29747,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the East Pillar 2026 Irrevocable Trust (the \"Trust\"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity.  The reporting person and certain of his immediate family members are beneficiaries of the Trust."}],"balance_after":29747,"derivative":{"exercise_price":10.9,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":29747},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706832,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":false,"shares":29747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":29747},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706831,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":true,"shares":7639,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the East Pillar 2026 Irrevocable Trust (the \"Trust\"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity.  The reporting person and certain of his immediate family members are beneficiaries of the Trust."}],"balance_after":7639,"derivative":{"exercise_price":16.41,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":7639},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706830,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":false,"shares":7639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025."}],"balance_after":0,"derivative":{"exercise_price":16.41,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":7639},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706829,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":true,"shares":19441,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the East Pillar 2026 Irrevocable Trust (the \"Trust\"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity.  The reporting person and certain of his immediate family members are beneficiaries of the Trust."}],"balance_after":19441,"derivative":{"exercise_price":12.46,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":19441},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706828,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":false,"shares":19441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":12.46,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":19441},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706827,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the East Pillar 2026 Irrevocable Trust (the \"Trust\"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity.  The reporting person and certain of his immediate family members are beneficiaries of the Trust."}],"balance_after":21000,"derivative":{"exercise_price":12.96,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706826,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":false,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023."}],"balance_after":0,"derivative":{"exercise_price":12.96,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706825,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":true,"shares":11650,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the East Pillar 2026 Irrevocable Trust (the \"Trust\"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity.  The reporting person and certain of his immediate family members are beneficiaries of the Trust."}],"balance_after":11650,"derivative":{"exercise_price":40.37,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":11650},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706824,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":false,"shares":11650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022."}],"balance_after":0,"derivative":{"exercise_price":40.37,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":11650},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706823,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":true,"shares":14777,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the East Pillar 2026 Irrevocable Trust (the \"Trust\"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity.  The reporting person and certain of his immediate family members are beneficiaries of the Trust."}],"balance_after":14777,"derivative":{"exercise_price":26.53,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":14777},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706822,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":false,"shares":14777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021."}],"balance_after":0,"derivative":{"exercise_price":26.53,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":14777},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706821,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":true,"shares":29555,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the East Pillar 2026 Irrevocable Trust (the \"Trust\"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity.  The reporting person and certain of his immediate family members are beneficiaries of the Trust."}],"balance_after":29555,"derivative":{"exercise_price":28.8,"expiration_date":"2029-09-09","underlying":"Common Stock","underlying_shares":29555},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":706820,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:37:22.000Z","date":"2026-07-16","kind":"gift","planned":false,"acquired":false,"shares":29555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable.  Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022."}],"balance_after":0,"derivative":{"exercise_price":28.8,"expiration_date":"2029-09-09","underlying":"Common Stock","underlying_shares":29555},"source":{"system":"sec-edgar","filing":"0001404955-26-000006","document":"form4-07172026_080716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000006/form4-07172026_080716.xml","form_type":"4"}},{"id":747884,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-06-05T20:26:13.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":17786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full on the earlier of:  (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":17786,"derivative":{"exercise_price":29.46,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":17786},"source":{"system":"sec-edgar","filing":"0001404955-26-000002","document":"form4-06052026_080609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000140495526000002/form4-06052026_080609.xml","form_type":"4"}},{"id":976205,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":19.97,"expiration_date":"2029-11-08","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":976204,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":25.2,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":976203,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":26.32,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":976202,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":976201,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":976200,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-08","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":976199,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9398,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"Company RSUs\") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":976198,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":148063,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the Reporting Person is the manager. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":976197,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:21:18.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":136301,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312127/ownership.xml","form_type":"4"}},{"id":1121427,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T16:06:12.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":9398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":145699,"source":{"system":"sec-edgar","filing":"0000950170-25-082310","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025082310/ownership.xml","form_type":"4"}},{"id":1122851,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-05T00:33:05.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":29747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full on the earlier of:  (i) June 3, 2026 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":29747,"derivative":{"exercise_price":10.9,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":29747},"source":{"system":"sec-edgar","filing":"0001415889-25-015698","document":"form4-06052025_120602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000141588925015698/form4-06052025_120602.xml","form_type":"4"}},{"id":1483548,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T17:22:56.000Z","date":"2024-06-08","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (i) June 7, 2025, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":26000,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-072063","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024072063/ownership.xml","form_type":"4"}},{"id":1486728,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-06-07T20:32:41.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":7639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full on the earlier of:  (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":7639,"derivative":{"exercise_price":16.41,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":7639},"source":{"system":"sec-edgar","filing":"0001415889-24-015991","document":"form4-06072024_080638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000141588924015991/form4-06072024_080638.xml","form_type":"4"}},{"id":1843493,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-27T17:48:04.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 23, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-23-030213","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023030213/ownership.xml","form_type":"4"}},{"id":1854285,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-15T22:23:29.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":19441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date."}],"balance_after":19441,"derivative":{"exercise_price":12.46,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":19441},"source":{"system":"sec-edgar","filing":"0001209191-23-037530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919123037530/doc4.xml","form_type":"4"}},{"id":2098420,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T17:48:56.000Z","date":"2022-11-30","kind":"sale","acquired":false,"shares":5179,"price":47.6044,"value":246543.1876,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $47.93, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":148063,"source":{"system":"sec-edgar","filing":"0000899243-22-037475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322037475/doc4.xml","form_type":"4"}},{"id":2098419,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T17:48:56.000Z","date":"2022-11-30","kind":"sale","acquired":false,"shares":6851,"price":46.4355,"value":318129.6105,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.28 to $47.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":153242,"source":{"system":"sec-edgar","filing":"0000899243-22-037475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322037475/doc4.xml","form_type":"4"}},{"id":2098418,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T17:48:56.000Z","date":"2022-11-30","kind":"sale","acquired":false,"shares":4779,"price":47.6044,"value":227501.4276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $47.93, inclusive."}],"balance_after":136301,"source":{"system":"sec-edgar","filing":"0000899243-22-037475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322037475/doc4.xml","form_type":"4"}},{"id":2098417,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T17:48:56.000Z","date":"2022-11-30","kind":"sale","acquired":false,"shares":6322,"price":46.4355,"value":293565.231,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.28 to $47.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":141080,"source":{"system":"sec-edgar","filing":"0000899243-22-037475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322037475/doc4.xml","form_type":"4"}},{"id":2128507,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-01T17:38:03.000Z","date":"2022-10-28","kind":"sale","acquired":false,"shares":869,"price":41.1204,"value":35733.6276,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.27, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":160093,"source":{"system":"sec-edgar","filing":"0000899243-22-034709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034709/doc4.xml","form_type":"4"}},{"id":2128506,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-01T17:38:03.000Z","date":"2022-10-28","kind":"sale","acquired":false,"shares":22096,"price":40.279,"value":890004.784,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":160962,"source":{"system":"sec-edgar","filing":"0000899243-22-034709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034709/doc4.xml","form_type":"4"}},{"id":2128505,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-01T17:38:03.000Z","date":"2022-10-28","kind":"sale","acquired":false,"shares":800,"price":41.1204,"value":32896.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.27, inclusive."}],"balance_after":147402,"source":{"system":"sec-edgar","filing":"0000899243-22-034709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034709/doc4.xml","form_type":"4"}},{"id":2128504,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-01T17:38:03.000Z","date":"2022-10-28","kind":"sale","acquired":false,"shares":20338,"price":40.279,"value":819194.302,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":148202,"source":{"system":"sec-edgar","filing":"0000899243-22-034709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034709/doc4.xml","form_type":"4"}},{"id":2131079,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-27","kind":"sale","acquired":false,"shares":4013,"price":43.2321,"value":173490.4173,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.495, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by the LLC. The reporting person is the manager of the LLC."}],"balance_after":183058,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131078,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-27","kind":"sale","acquired":false,"shares":23719,"price":42.0299,"value":996907.1981,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.72 to $42.715, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by the LLC. The reporting person is the manager of the LLC."}],"balance_after":187071,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131077,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-27","kind":"sale","acquired":false,"shares":44440,"price":41.1156,"value":1827177.264,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.715, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by the LLC. The reporting person is the manager of the LLC."}],"balance_after":210790,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131076,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-27","kind":"sale","acquired":false,"shares":3693,"price":43.2321,"value":159656.1453,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.495, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."}],"balance_after":168540,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131075,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-27","kind":"sale","acquired":false,"shares":21830,"price":42.0299,"value":917512.717,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.72 to $42.715, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."}],"balance_after":172233,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131074,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-27","kind":"sale","acquired":false,"shares":40903,"price":41.1156,"value":1681751.3868,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.715, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."}],"balance_after":194063,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131073,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":20085,"price":44.9002,"value":901820.517,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.635 to $45.14, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by the LLC. The reporting person is the manager of the LLC."}],"balance_after":255230,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131072,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":12537,"price":43.9749,"value":551313.3213,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.63 to $44.615, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by the LLC. The reporting person is the manager of the LLC."}],"balance_after":275315,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131071,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":38961,"price":43.0756,"value":1678268.4516,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.63 to $43.625, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by the LLC. The reporting person is the manager of the LLC."}],"balance_after":287852,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131070,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":18486,"price":44.9002,"value":830025.0972,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.635 to $45.14, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."}],"balance_after":234966,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131069,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":11539,"price":43.9749,"value":507426.3711,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.63 to $44.615, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."}],"balance_after":253452,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131068,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":35860,"price":43.0756,"value":1544691.016,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.63 to $43.625, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."}],"balance_after":264991,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131067,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":4906,"price":44.9163,"value":220359.3678,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by the LLC. The reporting person is the manager of the LLC."}],"balance_after":326813,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2131066,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T21:50:11.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":4515,"price":44.9163,"value":202797.0945,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. (\"ATP GP\"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the \"LLC\"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\") reporting ownership of Common Stock (the \"Distribution\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution."}],"balance_after":300851,"source":{"system":"sec-edgar","filing":"0000899243-22-034377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322034377/doc4.xml","form_type":"4"}},{"id":2239118,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-08T21:00:35.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest on June 7, 2023 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":12.96,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-22-035077","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919122035077/doc4.xml","form_type":"4"}},{"id":2244917,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:25:49.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-020953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322020953/doc4.xml","form_type":"4"}},{"id":2654763,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-06-25T20:57:20.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":11650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's  continued service on such  vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the reporting person's arrangement with Apple Tree Life Sciences, Inc. (the \"Manager\"), the reporting person holds the option for the benefit of Apple Tree Partners IV, L.P. (the \"Fund\"). The reporting person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The reporting person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":11650,"derivative":{"exercise_price":40.37,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":11650},"source":{"system":"sec-edgar","filing":"0001209191-21-043330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919121043330/doc4.xml","form_type":"4"}},{"id":2683495,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T17:56:49.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":13000,"derivative":{"exercise_price":26.32,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-21-076498","document":"tm2118278-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921076498/tm2118278-4_4seq1.xml","form_type":"4"}},{"id":2966179,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-25T22:03:32.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":375000,"price":39,"value":14625000.0,"ownership":{"direct":false,"nature":"By Apple Tree Partners IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held by Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\") is the sole general partner of ATP IV. The reporting person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV, but disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":17161713,"source":{"system":"sec-edgar","filing":"0001209191-20-060543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919120060543/doc4.xml","form_type":"4"}},{"id":3083712,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-14T16:45:54.000Z","date":"2020-07-10","kind":"purchase","acquired":true,"shares":415000,"price":36,"value":14940000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 10, 2020, Apple Tree Partners IV, L.P. (\"ATP\") purchased 415,000 shares of common stock of the Issuer at a price of $36.00 per share pursuant to an underwritten public offering. These shares are owned directly by ATP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP."}],"balance_after":5830203,"source":{"system":"sec-edgar","filing":"0001104659-20-083453","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465920083453/a4.xml","form_type":"4"}},{"id":3120383,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-05T21:26:25.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":14777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's  continued service on such  vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the reporting person's arrangement with Apple Tree Life Sciences, Inc. (the \"Manager\"), the reporting person holds the option for the benefit of Apple Tree Partners IV, L.P. (the \"Fund\"). The reporting person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The reporting person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":14777,"derivative":{"exercise_price":26.53,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":14777},"source":{"system":"sec-edgar","filing":"0001209191-20-034729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919120034729/doc4.xml","form_type":"4"}},{"id":3127260,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T18:52:50.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Apple Tree Venture Management, LLC (the \"Management Company\"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the \"Fund\"). The Reporting Person is obligated to turn over to the Management Company any net cash received upon exercise of the option and sale of the underlying common stock, which will offset management fees owed by the Fund to the Management Company. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":13000,"derivative":{"exercise_price":25.2,"expiration_date":"2030-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-20-069071","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465920069071/a4.xml","form_type":"4"}},{"id":3374714,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-12T19:03:09.000Z","date":"2019-11-08","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Apple Tree Venture Management, LLC (the \"Management Company\"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the \"Fund\"). The Reporting Person is obligated to turn over to the Management Company any net cash received upon exercise of the option and sale of the underlying common stock, which will offset management fees owed by the Fund to the Management Company. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":26000,"derivative":{"exercise_price":19.97,"expiration_date":"2029-11-07","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001104659-19-062784","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919062784/a4.xml","form_type":"4"}},{"id":3416259,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-09-13T00:11:08.000Z","date":"2019-09-10","kind":"grant","acquired":true,"shares":29555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest (i) 1/12th of the total shares on June 21, 2019; and then (ii) quarterly as to 1/12th of the total shares, commencing the first quarter following June 21, 2019, subject to Reporting Person's continued service through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with Apple Tree Life Sciences, Inc. (the \"Manager\"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the \"Fund\").   The Reporting Person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":29555,"derivative":{"exercise_price":28.8,"expiration_date":"2019-09-09","underlying":"Common Stock","underlying_shares":29555},"source":{"system":"sec-edgar","filing":"0001567619-19-018225","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919018225/doc1.xml","form_type":"4"}},{"id":3478804,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-06-25T18:05:07.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":880568,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":286439},"source":{"system":"sec-edgar","filing":"0001104659-19-037458","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037458/a4.xml","form_type":"4"}},{"id":3478803,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-06-25T18:05:07.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":13000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4228764},"source":{"system":"sec-edgar","filing":"0001104659-19-037458","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037458/a4.xml","form_type":"4"}},{"id":3478802,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T18:05:07.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":900000,"price":16,"value":14400000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"On June 24, 2019, ATP purchased 900,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP."}],"balance_after":5415203,"source":{"system":"sec-edgar","filing":"0001104659-19-037458","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037458/a4.xml","form_type":"4"}},{"id":3478801,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T18:05:07.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":286439,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the total number of shares of common stock received by ATP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP."}],"balance_after":4515203,"source":{"system":"sec-edgar","filing":"0001104659-19-037458","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037458/a4.xml","form_type":"4"}},{"id":3478800,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T18:05:07.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":4228764,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the total number of shares of common stock received by Apple Tree Partners IV, L.P. (\"ATP\") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP."}],"balance_after":4228764,"source":{"system":"sec-edgar","filing":"0001104659-19-037458","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037458/a4.xml","form_type":"4"}},{"id":3481436,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-06-21T21:01:27.000Z","date":"2019-06-21","kind":"exercise","acquired":false,"shares":2799910,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Apple Tree Partners IV, L. P"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV.  Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2799910},"source":{"system":"sec-edgar","filing":"0001567619-19-013840","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/doc1.xml","form_type":"4"}},{"id":3481435,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2019-06-21T21:01:27.000Z","date":"2019-06-21","kind":"exercise","acquired":false,"shares":7617746,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Apple Tree Partners IV, L. P"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV.  Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7617746},"source":{"system":"sec-edgar","filing":"0001567619-19-013840","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/doc1.xml","form_type":"4"}},{"id":3481434,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-06-21T21:01:27.000Z","date":"2019-06-21","kind":"exercise","acquired":false,"shares":4980168,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Apple Tree Partners IV, L. P"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV.  Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4980168},"source":{"system":"sec-edgar","filing":"0001567619-19-013840","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/doc1.xml","form_type":"4"}},{"id":3481433,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:01:27.000Z","date":"2019-06-21","kind":"purchase","acquired":true,"shares":1388889,"price":18,"value":25000002.0,"ownership":{"direct":false,"nature":"By Apple Tree Partners IV, L. P"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV.  Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":16786713,"source":{"system":"sec-edgar","filing":"0001567619-19-013840","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/doc1.xml","form_type":"4"}},{"id":3481432,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:01:27.000Z","date":"2019-06-21","kind":"exercise","acquired":true,"shares":2799910,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Apple Tree Partners IV, L. P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV.  Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":15397824,"source":{"system":"sec-edgar","filing":"0001567619-19-013840","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/doc1.xml","form_type":"4"}},{"id":3481431,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:01:27.000Z","date":"2019-06-21","kind":"exercise","acquired":true,"shares":7617746,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Apple Tree Partners IV, L. P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV.  Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":12597914,"source":{"system":"sec-edgar","filing":"0001567619-19-013840","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/doc1.xml","form_type":"4"}},{"id":3481430,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":29760,"kind":"person","name":"Harrison Seth Loring","position":1,"cik":"0001404955","reported_name":"Harrison Seth Loring","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:01:27.000Z","date":"2019-06-21","kind":"exercise","acquired":true,"shares":4980168,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Apple Tree Partners IV, L. P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV.  Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":4980168,"source":{"system":"sec-edgar","filing":"0001567619-19-013840","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/doc1.xml","form_type":"4"}}]}